OLD National Bancorp IN decreased its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 52.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,260 shares of the company’s stock after selling 9,185 shares during the quarter. OLD National Bancorp IN’s holdings in Axsome Therapeutics were worth $509,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Axsome Therapeutics by 2.2% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 16,793 shares of the company’s stock worth $1,036,000 after purchasing an additional 361 shares in the last quarter. Lion Street Advisors LLC grew its holdings in shares of Axsome Therapeutics by 14.8% during the first quarter. Lion Street Advisors LLC now owns 15,132 shares of the company’s stock worth $933,000 after purchasing an additional 1,955 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its holdings in shares of Axsome Therapeutics by 15.0% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 1,981 shares of the company’s stock worth $153,000 after purchasing an additional 258 shares in the last quarter. MetLife Investment Management LLC grew its holdings in shares of Axsome Therapeutics by 3.4% during the fourth quarter. MetLife Investment Management LLC now owns 16,900 shares of the company’s stock worth $1,303,000 after purchasing an additional 558 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. purchased a new position in shares of Axsome Therapeutics during the fourth quarter worth about $259,000. Hedge funds and other institutional investors own 72.70% of the company’s stock.
Axsome Therapeutics Price Performance
Shares of Axsome Therapeutics stock opened at $70.24 on Tuesday. The company has a quick ratio of 2.95, a current ratio of 3.02 and a debt-to-equity ratio of 1.32. The company has a market cap of $3.06 billion, a PE ratio of -18.48 and a beta of 1.84. The business has a 50 day moving average of $76.10 and a 200 day moving average of $70.23. Axsome Therapeutics, Inc. has a 52 week low of $35.16 and a 52 week high of $91.29.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on AXSM. StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 11th. Morgan Stanley upped their target price on Axsome Therapeutics from $83.00 to $87.00 in a research note on Tuesday, May 9th. Guggenheim upped their target price on Axsome Therapeutics from $90.00 to $100.00 in a research note on Tuesday, May 9th. Mizuho upped their target price on Axsome Therapeutics from $84.00 to $95.00 in a research note on Thursday, May 11th. Finally, VNET Group reaffirmed a “reiterates” rating on shares of Axsome Therapeutics in a research note on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $103.69.
Axsome Therapeutics Profile
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
See Also
- Five stocks we like better than Axsome Therapeutics
- Tesla Production Cranks Into High Gear, Shares Follow
- Ford Soars 30% YTD After Breaking Out: What’s Next?
- Acuity Brands Lights Up Opportunity In The Industrial Sector
- Overstock Looks Beyond Overbought After Bed Bath Re-Brand
- Tecnoglass Shines Bright As Analysts Bullish On Growth Potential
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
